Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05254795 · ClinicalTrials.gov registry record · NA
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
A NA study of Non-Small Cell Lung Cancer, sponsored by Timothy Mullett.
- Active
- Registry status
- NA
- Development phase
- 659
- Enrollment target
- 1
- Study location
NCT05254795: Active NA study of Non-Small Cell Lung Cancer, sponsored by Timothy Mullett.
NCT05254795 is a NA study of Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Timothy Mullett. The registered enrollment target is 659 participants, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05254795, a NA study of Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Timothy Mullett.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 659 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Primary Outcome
Overall survival 1 year survival between individuals with stage IIb-IV NSCLC who receive MTB assisted care to those who receive usual care.
Conditions Studied
Interventions
- OTHER Molecular tumor board assisted care
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 659 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2026-12-22 |
| Phase | NA |
What the registry record for NCT05254795 still lists
NCT05254795 is an interventional study that assigns participants to a tested intervention. The registered 659 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 651-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Molecular tumor board assisted care is the first listed.
NCT05254795 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT05254795 about?
NCT05254795 is a clinical study titled "Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care". This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
What is the current status of trial NCT05254795?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 659 participants. The study started on 2022-04-13. Estimated completion is 2026-12-22.
What conditions does trial NCT05254795 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05254795?
The interventions under investigation include: Molecular tumor board assisted care (OTHER).
Who is sponsoring clinical trial NCT05254795?
This trial is sponsored by Timothy Mullett, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05254795 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05254795's enrollment target sits among peer trials
659 49th of 454 higher than 406 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dyadic Yoga Program for Patients Undergoing Thoracic Radiotherapy and Their Family Caregivers: The Testing of a Mobile Application Delivery
RECRUITING · NA
-
High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07216742 · 659 participants · Phase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI